New cutting edge technology can be used to grade cancer tumours, eradicating human subjectivity and ensuring patients get the right treatment.
A new imaging technology to grade tumour biopsies has been developed by a team of scientists led by the Department of Physics and the Department of Surgery and Cancer at Imperial College London.
Publishing their results today in the journal Convergent Science Physical Oncology, they describe how their new method promises to significantly reduce the subjectivity and variability in grading the severity of cancers.
[Digistain] is an extremely reliable indicator of the degree of progression of the disease. Because it is based on a physical measurement, rather than a human judgement, it promises to remove the element of chance in cancer diagnosis.Professor Chris Phillips
Nearly all cancers are still diagnosed by doctors taking a sample of the tumour, a so-called biopsy, then slicing it thinly and staining it with two vegetable dyes used for more than 100 years. They look at this ‘H+E stained’ sample under a microscope and then judge the severity of the disease by eye alone.
Life-changing treatment decisions have to be based on this ‘grading’ process, yet it is well known that different practitioners given the same slice will only agree on its grade about 70% of the time, resulting in an overtreatment problem.
The team’s new ‘Digistain’ technology addresses this problem by using invisible mid-infrared light to photograph the tissue slices in a way that maps out the chemical changes that signal the onset of cancer. In particular, they measure the ‘nuclear-to-cytoplasmic-ratio’ (NCR): a recognized biological marker for a wide range of cancers.
Lead author Professor Chris Phillips, from the Department of Physics at Imperial, said: “Our machine gives a quantitative ‘Digistain index’ (DI) score, corresponding to the NCR, and this study shows that it is an extremely reliable indicator of the degree of progression of the disease. Because it is based on a physical measurement, rather than a human judgement, it promises to remove the element of chance in cancer diagnosis. “
In the experiment reported today, the team carried out a double-blind clinical pilot trial using two adjacent slices taken from 75 breast cancer biopsies. The first slice was graded by clinicians as usual, using the standard H+E protocol. It was also used to identify the so-called ‘region of interest’ (RoI), i.e. the part of the slice containing the tumour.
The team then used the Digistain imager to get a DI value averaged over the corresponding RoI on the other, unstained slice, and ran a statistical analysis on the results.
Professor Phillips said: “Even with this modest number of samples, the correlation we saw between the DI score and the H+E grade would only happen by chance 1 time in 1400 trials. The strength of this correlation makes us extremely optimistic that Digistain will be able to eliminate subjectivity and variability in biopsy grading.”
Proving its worth
The NCR factor that Digistain measures is known to be common to a wide range of cancers, as it occurs when the reproductive cell cycle gets disrupted in the tumour and cell nuclei get distorted with rogue DNA. It is likely that in the long run, Digistain could help with the diagnosis of all different types of cancer.
At a practical level, the researchers say that the Digistain imaging technology can easily and cheaply be incorporated into existing hospital labs, and be used by their staff. Professor Philips added: “It’s easy to prove its worth by checking it with the thousands of existing biopsy specimens that are already held in hospital archives. Together these facts will smooth the path into the clinic, and it could be saving lives in only a couple of years.”
The Latest on: Cancer diagnosis
via Google News
The Latest on: Cancer diagnosis
- Colon Cancer Dieton May 11, 2020 at 5:07 pm
What you should eat and avoid to lower your risk of developing colorectal cancer. Every year, colorectal cancer claims tens of thousands of lives in the U.S. The American Cancer Society estimates that ...
- Insulin resistance contributes to racial disparities in breast cancer prognosis in US women, Mount Sinai researchers revealon May 11, 2020 at 5:06 pm
New study identifies that differences in insulin resistance can explain in part the disparities in breast cancer survival between black and white women.
- Learning you have cancer in the time of coronavirus | Raleigh News & Observeron May 11, 2020 at 3:15 pm
Crystal Johnson of Clayton, N.C., who was diagnosed with kidney cancer in April 2020, talks about the fear, loneliness and challenges that come from getting the diagnosis during the coronavirus ...
- Novel artificial intelligence system increases the detection of prostate cancer in whole slide images of core needle biopsieson May 11, 2020 at 9:31 am
Prostate cancer (PrCa) is the second most common cancer among men in the United States. The gold standard for detecting PrCa is the examination of prostate needle core biopsies. Diagnosis can be ...
- Decline in cancer diagnoses due to corona crisison May 11, 2020 at 8:12 am
Cancer care has dramatically changed as a result of the measures taken during the COVID-19 pandemic: Many patients have not been going to their GPs, or putting it off, and have been referred to the ...
- Kristen Biel lost her job after cancer diagnosis. The Supreme Court will decide if she's barred from suing.on May 11, 2020 at 5:38 am
Courts have long acknowledged an exception in the law that keeps "ministers" of a faith from bringing employment discrimination claims against their religious employers, capped by a unanimous Supreme ...
- Non-Small Cell Lung Cancer (NSCLC) Market Insights and Epidemiology 2017-2030 - ResearchAndMarkets.comon May 11, 2020 at 5:18 am
Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
- Reducing Risk Of Fatal Breast Cancer, Study Confirms Strategyon May 11, 2020 at 5:12 am
Researchers analyzed more than a half million women in Sweden and found early mammogram screening significantly reduces the rates of advanced and fatal breast cancer. Their findings are published ...
- Early mammography screening lowers risk of developing fatal breast canceron May 11, 2020 at 12:32 am
An analysis of more than half a million women in Sweden reveals that mammography screening reduces the rates of advanced and fatal breast cancers. The findings are published early online in Cancer.
via Bing News